TrialThe international journal of cardiovascular imaging2025

Impact of alirocumab on neoatherosclerosis formation and vessel healing after drug-eluting stent implantation in patients with acute myocardial infarction: a substudy of the PACMAN-AMI trial.

Ryota Kakizaki et al.PubMed ↗Full text ↗Publisher ↗

Alirocumabno clear effectHigher neointimal thickness, no range given, higher minimal fibrous cap thickness, no range given.No ranges given.

What the trial testedas reported · 191 people · 2025

No range given

Reported higher neointimal thickness, no range given

+136

alirocumab vs placebo

As reported

difference 136.2, no interval

No range given

Reported higher neointimal thickness, no range given

+151

alirocumab vs placebo

As reported

difference 151.4, no interval

No range given

Reported higher minimal fibrous cap thickness, no range given

+218

alirocumab vs placebo, in patients with lipid-laden neointima

As reported

difference 217.5, no interval

No range given

Reported higher minimal fibrous cap thickness, no range given

+87.8

alirocumab vs placebo, in patients with lipid-laden neointima

As reported

difference 87.8, no interval

Who was studied, and how

191people with dyslipidemia, in this paper

The trial randomly assignedassigned by chance

alirocumab

placebo

Reported higher neointimal thickness, no range given+136

randomised

Among patients with lipid-laden neointima, the trial randomly assignedassigned by chance

alirocumab

placebo

Reported higher minimal fibrous cap thickness, no range given+218

randomised

the abstract, start to end

Neointimal thickness (136.2 ± 71.1 vs. 151.4 ± 101.4 μm, P = 0.45) and the …

… group than in the placebo group (217.5 ± 122.5 vs. 87.8 ± 49.1 μm, P = 0.02).

← favours treatmentfavours comparator →

could be chance

No interval given · direction only, strength unknown

Neointimal thicknessalirocumab vs placebo

136.2

Neointimal thicknessalirocumab vs placebo

151.4

Minimal fibrous cap thicknessalirocumab vs placebo, in patients with lipid-laden neointima

217.5

Minimal fibrous cap thicknessalirocumab vs placebo, in patients with lipid-laden neointima

87.8

PCSK9 inhibitorsCardiac & vascular functionLiver & MASLD

1 / 4

Impact of alirocumab on neoatherosclerosis formation and vessel healing after drug-eluting stent implantation in patients with acute myocardial infarction: a substudy of the PACMAN-AMI trial.

What the trial testedas reported · 191 people · 2025

Reported higher neointimal thickness, no range given

Reported higher neointimal thickness, no range given

Reported higher minimal fibrous cap thickness, no range given

Reported higher minimal fibrous cap thickness, no range given

Who was studied, and how

Four numbers in the abstract

Where each one falls

Where it lands on the map

Not cited yet